Milbemycin Oxime
Who holds supplier records for Milbemycin Oxime? 4 organisations hold a current record for Milbemycin Oxime: an active US FDA Type II Drug Master File or a CEP. 4 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (2); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Milbemycin Oxime: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/milbemycin-oxime
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in China
2 of the 2 current records with a recorded country list China. Organisation country is not necessarily the manufacturing site.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Milbemycin Oxime. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Chongqing Daxin Pharmaceutical Co., Ltd.ChinaCEP
- HUBEI HONCH PHARMACEUTICAL CO LTDCEP Company GMP cert on record
- LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDCEP Company GMP cert on record
- ChinaCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (4)
Certificates of Suitability on the EDQM register for Milbemycin Oxime, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 6 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO., LTD. Fuzhou | CN | CEP 2018-024 - Rev 05 Milbemycin oxime for veterinary use | Nov 2026 | Inspected Apr 2025 Germany |
| HUBEI HONCH PHARMACEUTICAL CO., LTD. Huanggang | CN | CEP 2018-025 - Rev 04 Milbemycin oxime for veterinary use | Jan 2025 | Inspected Feb 2025 Switzerland |
| Zhejiang Hisun Pharmaceutical Co., Ltd. Taizhou City | CN | CEP 2021-391 - Rev 02 Milbemycin oxime for veterinary use | Apr 2024 | — |
| CHONGQING DAXIN PHARMACEUTICAL CO., LTD. Shuitu Town | CN | R0-CEP 2020-241 - Rev 00 Milbemycin oxime for veterinary use | Sept 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Overview
Milbemycin Oxime is an active pharmaceutical ingredient with CAS number 129496-10-2.
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Milbemycin Oxime?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Milbemycin Oxime: Chongqing Daxin Pharmaceutical Co., Ltd. (China), HUBEI HONCH PHARMACEUTICAL CO LTD, LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD and Zhejiang Hisun Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Does Milbemycin Oxime have a European Certificate of Suitability?
Yes. 4 organisations hold a valid CEP for Milbemycin Oxime on the EDQM register, including LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO., LTD. Fuzhou (CN), HUBEI HONCH PHARMACEUTICAL CO., LTD. Huanggang (CN), Zhejiang Hisun Pharmaceutical Co., Ltd. Taizhou City (CN) and CHONGQING DAXIN PHARMACEUTICAL CO., LTD. Shuitu Town (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Milbemycin Oxime supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Milbemycin Oxime?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.